Verrica Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Verrica Pharmaceuticals generated cash of -$38,577,000, which is less than the previous year. Cash used in financing activities reached the amount of $74,213,000 last year. Net change in cash is therefore $35,274,000.
Cash Flow
| 2016 | -1.61M | 0 | 483K |
|---|---|---|---|
| 2017 | -4.58M | 0 | 12.71M |
| 2018 | -17.87M | -79.89M | 99.37M |
| 2019 | -27.40M | 25.95M | 423K |
| 2020 | -30.20M | -3.58M | 35.23M |
| 2021 | -27.58M | -998K | 33.64M |
| 2022 | -18.65M | 54.04M | -16.87M |
| 2023 | -38.57M | -362K | 74.21M |
VRCA Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 34.27M | 15.75M | 10.68M | 9.24M | 10.27M | 8.66M | 527K | 1.65M |
Operating activities | ||||||||
Net income | -66.99M | -24.48M | -35.08M | -42.69M | -28.20M | -20.64M | -4.45M | -1.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 836K | 718K | 472K | 229K | 257K | 20K | 0 | 0 |
Stock-based compensation expense | 14.37M | 4.98M | 6.05M | 9.82M | 3.33M | 0 | 82K | 9K |
| Deferred income tax benefit | 14.37M | 4.98M | 6.05M | 9.82M | 3.33M | 0 | 82K | 9K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -3.92M | -487K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 487K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.20M | -338K | 497K | -838K | 225K | 793K | 64K | 71K |
Cash generated by operating activities | -38.57M | -18.65M | -27.58M | -30.20M | -27.40M | -17.87M | -4.58M | -1.61M |
Investing activities | ||||||||
Purchases Of Investments | 0 | -4.48M | -68.91M | -71.73M | -89.85M | -79.12M | 0 | 0 |
Investments In Property Plant And Equipment | -362K | -302K | -883K | -1.47M | -682K | -774K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -362K | 54.04M | -998K | -3.58M | 25.95M | -79.89M | 0 | 0 |
Financing activities | ||||||||
Common Stock Issued | 30.3M | 26.90M | 28.11M | 453K | 423K | 86.25M | 12.71M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 44.08M | -43.75M | -5K | -34.16M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 74.21M | -16.87M | 33.64M | 35.23M | 423K | 99.37M | 12.71M | 483K |
Net Change In Cash | 35.27M | 18.52M | 5.06M | 1.44M | -1.03M | 1.60M | 8.13M | -1.12M |
Cash at end of period | 69.54M | 34.27M | 15.75M | 10.68M | 9.24M | 10.27M | 8.66M | 527K |
| Data source | Data source | Data source | Data source | Data source | Data source |